Hemostemix (CVE:HEM) Trading Up 29.4% – Still a Buy?

Hemostemix Inc. (CVE:HEM) was up 29.4% during trading on Friday . The company traded as high as C$0.11 and last traded at C$0.11. Approximately 602,760 shares were traded during mid-day trading, an increase of 511% from the average daily volume of 98,700 shares. The stock had previously closed at C$0.09.

Hemostemix Stock Performance

The firm’s 50-day moving average price is C$0.09 and its 200-day moving average price is C$0.10. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The stock has a market cap of C$20.73 million, a P/E ratio of -4.07 and a beta of 1.25.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.